Velorum Therapeutics GTM brain

Velorum Therapeutics develops experimental heme biology medicines for people with porphyrias, cancer and heme-related injury.

category

Heme-targeted therapeutics

market profile

  • text: The pipeline describes porphyria and heme biologic programs; these are investigational, not established approved products.
  • text: NIH describes an experimental oncology program, VEL-03, supported by preclinical work.

personas

  • title: Hematologist at a porphyria center
    pains:
    • Patients with EPP or XLP can face severe light sensitivity and liver complications.
    • Needs reliable trial evidence and clear eligibility before considering an investigational treatment.
  • title: Oncology translational research leader
    pains:
    • Needs differentiated cancer mechanisms supported by reproducible evidence.
    • Must assess safety, patient selection and clinical translation before a partnership.
  • title: Biopharma business development leader
    pains:
    • Must distinguish compelling discovery science from a program ready for clinical investment.
    • Needs clarity on intellectual property, milestones and development rights.

icp

  • text: Rare disease centers with porphyria specialists are potential future clinical research stakeholders.
  • text: Biopharma partners with rare disease, oncology or biologic development capacity could be relevant as programs mature.

message pillars

  • text: Make heme biology the foundation of therapeutic discovery.
  • text: Explore an underappreciated therapeutic target.
  • text: Put patient needs at the center of development.

objections

  • objection: Is there proof of clinical safety and effectiveness?
    response: Request current trial status and program-specific data; the public pipeline describes investigational medicines.
  • objection: Why target heme biology?
    response: The company identifies disease-related problems involving heme synthesis or excess free heme; evidence must be assessed separately for each indication.

competitors

  • name: Disc Medicine
    why: Develops hematology treatments including programs in porphyria, creating disease-area overlap.
  • name: Alnylam Pharmaceuticals
    why: Develops rare disease medicines including porphyria treatments; indication and mechanism differ.

influencers

  • name: Pouya Modareszadeh
    why: Co-founder and CEO featured on the company's team page.
  • name: Parsa Modareszadeh
    why: Co-founder and president featured on the company's team page.

keywords

  • heme therapeutics
  • erythropoietic protoporphyria research
  • X-linked protoporphyria treatments
  • heme metabolism cancer
  • porphyria clinical development
  • heme injury therapeutics

voice

  • Science-led
  • Patient-centered
  • Hopeful

signals

  • text: A rare disease center is recruiting for porphyria research or expanding a specialist program.
  • text: A biopharma company is seeking external oncology or rare disease biologic programs.

pricing

model: unknown

motion

unknown

channels

  • scientific and patient community events

confidence

low

Founders

  • name: Pouya Modareszadeh
    title: Founder/CEO
    role: CEO
    bio: Co-Founder & CEO @ Velorum Therapeutics. Building new medicines.
  • name: Parsa Modareszadeh
    title: Founder/President
    role: Founder
    bio: Co-Founder and President @ Velorum Therapeutics. Goldwater Scholar. Working to create breakthrough medicines for devastating diseases.

Back to YC companies